Trial Outcomes & Findings for Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy (NCT NCT04831736)

NCT ID: NCT04831736

Last Updated: 2023-05-16

Results Overview

BPI Pain Severity Subscale consists of 4 questions (asking to rate pain). Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

31 participants

Primary outcome timeframe

24 Hours Post-Op (Day 2)

Results posted on

2023-05-16

Participant Flow

Participant milestones

Participant milestones
Measure
Treatment
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Overall Study
STARTED
15
16
Overall Study
COMPLETED
15
15
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Treatment
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Overall Study
Withdrawal by Subject
0
1

Baseline Characteristics

Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Total
n=30 Participants
Total of all reporting groups
Age, Continuous
48.9 years
n=99 Participants
46.5 years
n=107 Participants
47.3 years
n=206 Participants
Sex: Female, Male
Female
15 Participants
n=99 Participants
15 Participants
n=107 Participants
30 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
15 Participants
n=99 Participants
15 Participants
n=107 Participants
30 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
4 Participants
n=107 Participants
4 Participants
n=206 Participants
Race (NIH/OMB)
White
11 Participants
n=99 Participants
9 Participants
n=107 Participants
20 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
15 participants
n=99 Participants
15 participants
n=107 Participants
30 participants
n=206 Participants

PRIMARY outcome

Timeframe: 24 Hours Post-Op (Day 2)

BPI Pain Severity Subscale consists of 4 questions (asking to rate pain). Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
16.7 score on a scale
Standard Deviation 6.97
18.1 score on a scale
Standard Deviation 8.44

PRIMARY outcome

Timeframe: 48 Hours Post-Op (Day 3)

BPI Pain Severity Subscale consists of 4 questions (asking to rate pain). Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
16 score on a scale
Standard Deviation 5.32
15.7 score on a scale
Standard Deviation 9.36

SECONDARY outcome

Timeframe: Baseline (Day 0)

BPI Pain Severity Subscale is a 4-item questionnaire asking participants to rate pain. Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
3.5 score on a scale
Standard Deviation 6.45
2.2 score on a scale
Standard Deviation 5.37

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

BPI Pain Severity Subscale is a 4-item questionnaire asking participants to rate pain. Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
11.5 score on a scale
Standard Deviation 6.17
15 score on a scale
Standard Deviation 8.68

SECONDARY outcome

Timeframe: Baseline (Day 0)

BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.

Outcome measures

Outcome measures
Measure
Treatment
n=4 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=3 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
35 score on a scale
Standard Deviation 18.29
35 score on a scale
Standard Deviation 30.35

SECONDARY outcome

Timeframe: Day 1 Post-Op (Day 2)

BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
24.7 score on a scale
Standard Deviation 17.1
28.1 score on a scale
Standard Deviation 14.9

SECONDARY outcome

Timeframe: Day 2 Post-Op (Day 3)

BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
33.5 score on a scale
Standard Deviation 12.5
32.1 score on a scale
Standard Deviation 15.5

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
33.9 score on a scale
Standard Deviation 18.3
32.9 score on a scale
Standard Deviation 15.1

SECONDARY outcome

Timeframe: Day of Surgery (Day 1)

Use and dosage will be assessed through medical records and subject reports.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Total Dosage of Opioid Use
6 oral morphine equivalent (mg)
Standard Deviation 7.06
5 oral morphine equivalent (mg)
Standard Deviation 6.61

SECONDARY outcome

Timeframe: Day 1 Post-Op (Day 2)

Use and dosage will be assessed through medical records and subject reports.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Total Dosage of Opioid Use
21.5 oral morphine equivalent (mg)
Standard Deviation 17.9
37.2 oral morphine equivalent (mg)
Standard Deviation 61.4

SECONDARY outcome

Timeframe: Day 2 Post-Op (Day 3)

Use and dosage will be assess through medical records and subject reports.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Total Dosage of Opioid Use
21.2 oral morphine equivalent (mg)
Standard Deviation 31.1
18.5 oral morphine equivalent (mg)
Standard Deviation 21.2

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

Use and dosage will be assess through medical records and subject reports.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Total Dosage of Opioid Use
0.833 oral morphine equivalent (mg)
Standard Deviation 2.25
7 oral morphine equivalent (mg)
Standard Deviation 2.25

SECONDARY outcome

Timeframe: Baseline (Day 0)

The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
46.7 T-score
Standard Deviation 12.5
44.5 T-score
Standard Deviation 9.51

SECONDARY outcome

Timeframe: Day 1 Post-Op (Day 2)

The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
52.3 T-score
Standard Deviation 13.1
53.6 T-score
Standard Deviation 10.5

SECONDARY outcome

Timeframe: Day 2 Post-Op (Day 3)

The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
56.6 T-score
Standard Deviation 7.07
54 T-score
Standard Deviation 7.71

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
49.1 T-score
Standard Deviation 10.6
50.4 T-score
Standard Deviation 10.8

SECONDARY outcome

Timeframe: Baseline (Day 0)

The PROMIS Sleep Disturbance Short Form consists of 6 items assessing sleep disturbance. Each question is answered with a score of 1-5 (varies). The raw score is the sum of each item and ranges from 6-30. The raw score is converted to a T-score ranging from 31.7 to 76.1, with a standard deviation of 10. Higher T-scores indicate greater sleep disturbance.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (Short Form 6A) Score
53.6 T-score
Standard Deviation 5.39
49.2 T-score
Standard Deviation 10.1

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

The PROMIS Sleep Disturbance Short Form consists of 6 items assessing sleep disturbance. Each question is answered with a score of 1-5 (varies). The raw score is the sum of each item and ranges from 6-30. The raw score is converted to a T-score ranging from 31.7 to 76.1, with a standard deviation of 10. Higher T-scores indicate greater sleep disturbance.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (Short Form 6A) Score
51.7 T-score
Standard Deviation 9.19
50.7 T-score
Standard Deviation 9.2

SECONDARY outcome

Timeframe: Baseline (Day 0)

GAD-2 consists of 2 items and measures how often one has been bothered by anxiety-related problems. Each is answered with a score of 0 (not at all) to 3 (nearly every day). The total range of score is 0-6; the higher the score, the more frequent one is bothered by anxiety.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Generalized Anxiety Disorder (GAD-2) Score
2.47 score on a scale
Standard Deviation 1.77
1.87 score on a scale
Standard Deviation 2.07

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

GAD-2 consists of 2 items and measures how often one has been bothered by anxiety-related problems. Each is answered with a score of 0 (not at all) to 3 (nearly every day). The total range of score is 0-6; the higher the score, the more frequent one is bothered by anxiety.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Generalized Anxiety Disorder (GAD-2) Score
2.13 score on a scale
Standard Deviation 1.73
1.13 score on a scale
Standard Deviation 1.51

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

If the patient reports pain in the area of the breast, armpit, side of the body, or arm on the side of operation, the patient will be asked to report level of pain (0 is no pain and 10 is the worst pain imaginable). For each location, the total score is 0-10; the higher the score, the worse the pain. The total score is the sum of responses from each location.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Breast Cancer Pain Questionnaire (BCPQ) - Pain Score
3.53 score on a scale
Standard Deviation 2.56
4.6 score on a scale
Standard Deviation 2.72

SECONDARY outcome

Timeframe: Day 2 Post-Op (Day 3)

Part A of QoR-15 consists of 10 conditions. Based on how the patient has been feeling in the last 24 hours, they will respond to each condition using an 11-point Likert scale ranging from 0 to 10, where 0 is none of the time \[poor\] and 10 is all of the time \[excellent\]). The total range of score for Part A is 0-100; the higher the score, the better the participant has been feeling. Part B consists of 5 symptoms. The patient will indicate whether they have experienced each symptom over the last 24 hours using an 11-point Likert scale ranging from 10 to 0, where 10 is none of the time \[excellent\] and 0 is all of the time \[poor\]). The total range of score for Part B is 0-50; the higher the score, the better the participant has been feeling. The total score is the sum of of scores from Parts A and B. Total scores range from 0-150; the higher the score, the better the participant has been feeling.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Quality of Recovery (QoR-15) Survey Score
75.1 score on a scale
Standard Deviation 12
74.6 score on a scale
Standard Deviation 13.2

SECONDARY outcome

Timeframe: Day 7 Post-Op (Day 8)

Part A of QoR-15 consists of 10 conditions. Based on how the patient has been feeling in the last 24 hours, they will respond to each condition using an 11-point Likert scale ranging from 0 to 10, where 0 is none of the time \[poor\] and 10 is all of the time \[excellent\]). The total range of score for Part A is 0-100; the higher the score, the better the participant has been feeling. Part B consists of 5 symptoms. The patient will indicate whether they have experienced each symptom over the last 24 hours using an 11-point Likert scale ranging from 10 to 0, where 10 is none of the time \[excellent\] and 0 is all of the time \[poor\]). The total range of score for Part B is 0-50; the higher the score, the better the participant has been feeling. The total score is the sum of of scores from Parts A and B. Scores range from 0-150; the higher the score, the better the participant has been feeling.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Quality of Recovery (QoR-15) Survey Score
81.6 score on a scale
Standard Deviation 18.4
80.4 score on a scale
Standard Deviation 11.5

SECONDARY outcome

Timeframe: Day of Surgery (Day 1)

Side effects are calculated using a 7-item psycho-behavioral questionnaire. Participants indicate whether they have experienced any of the listed side effects of ketamine. The side effects listed on the questionnaire are not considered to be Adverse Events or Serious Adverse Events.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Number of Participants Who Experience Side Effects
7 Participants
7 Participants

SECONDARY outcome

Timeframe: Day 1 Post-Op (Day 2)

Side effects are calculated using a 7-item psycho-behavioral questionnaire. Participants indicate whether they have experienced any of the listed side effects. The side effects listed on the questionnaire are not considered to be Adverse Events or Serious Adverse Events.

Outcome measures

Outcome measures
Measure
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Number of Participants Who Experience Side Effects
8 Participants
5 Participants

Adverse Events

Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Lisa Doan, MD

NYU Langone Health

Phone: 212-201-1004

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place